October 29, 2026

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Notice of the Establishment of the Account Management Division

HEALIOS K.K. ("Healios") will establish an Account Management Division effective November 1, 2026, as part of its efforts to strengthen its organizational structure for the commercialization of the therapies it is currently developing.

Healios is advancing its business in the fields of somatic stem cell regenerative medicine and iPSC regenerative medicine, with the aim of bringing regenerative medicines into practical use. Healios is currently preparing to submit an application for approval of HLCM051 for the treatment of acute respiratory distress syndrome (ARDS). For cell therapies to take root in clinical practice, it is essential not only to deliver products to medical institutions but also to build ongoing relationships with them, including supporting the establishment of in-hospital operational systems for administration, promoting appropriate use, and collaborating with multidisciplinary healthcare professionals. In anticipation of a future commercial launch, Healios has decided to establish the Account Management Division as an organization that strategically manages medium- to long-term relationships with customers, including medical institutions.

The Account Management Division will be responsible for developing sales strategies, supporting the introduction of products at medical institutions, and providing information on appropriate use, among other activities, and will build the framework needed to deliver Healios' products to clinical practice.

About Healios:
HEALIOS K.K. is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells. In the somatic stem cell field, Healios is developing HLCM051(invimestrocel), a proprietary cell product comprised of multipotent adult progenitor cells ("MAPCs") derived from the bone marrow of healthy adult donors. HLCM051 has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in hundreds of patients across multiple indications. Healios is seeking to advance HLCM051 on a global basis for ARDS, trauma, and ischemic stroke. In the iPSC regenerative medicine field, Healios has developed HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-modification. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process. The development of AKT-01/HLCN061 is currently being led by our development partner, Akatsuki Therapeutics, Inc., in preparation for the initiation of clinical trials. Healios has also established a proprietary,

gene-edited “universal donor” induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).
https://www.healios.co.jp/en

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp